Neuromodulation—Who, What, When, Where and Why?

References 

1. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009;19:380
   • CrossRef
2. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102:774
   • CrossRef
3. Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn. 2008;27:28
   • CrossRef
4. Abrams P, Andersson KE, Birder L, et al. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. 4th International Consultation on Incontinence. Paris: Health Publication Ltd; 2009;
5. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009;2:CD004202
6. Bolton JF, Harrison SC. Neuromodulation 10 years on: how widely should we use this technique in bladder dysfunction?. Curr Opin Urol. 2009;19:375
   • CrossRef
7. Chapple C, De Ridder D. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?. BJU Int. 2009;[Epub ahead of print]
8. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy trial. J Urol. 2009;182:1055
   • Abstract
   • Full Text
   • Full-Text PDF (366 KB)
   • CrossRef
9. Sutherland SE, Lavers A, Carlson A, et al. Sacral nerve stimulation for voiding dysfunction: one institution's 11-year experience. Neurourol Urodyn. 2007;26:19
   • MEDLINE
   • CrossRef